Pujan Shah

Hi, sir. Thanks for the opportunity. So, my first question pertains to the previous participant. So, just to understand, as we have been developing the new molecules, we always been expecting molecules size of around Rs. 50 crores to Rs. 100 crores. So, are these new molecules have been in the range or it has been more than that?

Okay. Got it, sir. And so, we always, due to our Brownfield CAPEX, we were stating our asset turn would be around 2.5x to 3x as we commissioned our new plant in the same facility for at Pakhajan. So, should we consider it in the same range of commissioning of Rs. 250 crores of CAPEX?

And capacity utilization for the new CAPEX will be around 65%-70% in FY29?